The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
HOME > BUSINESS
BUSINESS
- Otsuka Pharma Pres. Iwamoto Dies at 54, Holding Firm CEO to Take Over
February 12, 2015
- Hypertension Most Commonly Treated Disease in Japan: Survey
February 12, 2015
- JCR Begins PI Study of Biosimilar for Fabry’s Disease Therapy
February 12, 2015
- Ixazomib, Successor to Velcade, Improved PFS in Interim Analysis of PIII Study: Takeda
February 12, 2015
- Once-Monthly Oral Ibandronate Filed for Approval in Japan: Chugai, Taisho
February 12, 2015
- Daiichi Sankyo Launches Edoxaban in US
February 10, 2015
- Sandoz K.K. Names Mr Hasegawa as New President
February 10, 2015
- Takeda Cuts Costs of 19.5 Billion Yen by December 2014
February 9, 2015
- Ethical Drug Sales Up 2.5% in December: Crecon Report
February 9, 2015
- Astellas to Set Up New Panel on Global Management
February 6, 2015
- Eisai Discloses Option Rights for AD Treatment under Deal with Biogen Idec
February 6, 2015
- Novartis Pharma Should Take Suspension Order Serious: Mr Tsuchiya of JSHP
February 5, 2015
- Daiichi Sankyo Initiates PIII Studies of Mirogabalin in Asia Including Japan
February 5, 2015
- Nipro’s Subsidiary to Build New Factory Eyeing Generic Market Expansion
February 5, 2015
- Wave of Downsizing (3): Mid-Sized Players Muted amid Industry’s Job-Shedding Drive
February 5, 2015
- Belsomra Again Grabs Number 1 Spot in December Anterio Ranking
February 4, 2015
- AbbVie Publishes Japanese PIII Study Results for Hepatitis C Treatment
February 4, 2015
- Astellas to Disclose Detailed Clinical Study Data on Approved Drugs
February 4, 2015
- Wave of Downsizing (2): Job Cuts at Non-Japanese Makers Also Come to Fore
February 4, 2015
- Astellas, Osaka University Join Hands in Cell Therapy Research
February 3, 2015
ページ
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…